Last reviewed · How we verify
Acerus Pharmaceuticals Corporation — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
2 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| NATESTO Testosterone Nasal Gel | NATESTO Testosterone Nasal Gel | marketed | Androgen replacement therapy | Androgen receptor | Endocrinology |
Therapeutic area mix
- Endocrinology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Abbott · 1 shared drug class
- Acrux DDS Pty Ltd · 1 shared drug class
- Alliance for Clinical Trials in Oncology · 1 shared drug class
- Bayer · 1 shared drug class
- Beersheva Mental Health Center · 1 shared drug class
- Clarus Therapeutics, Inc. · 1 shared drug class
- Imperial College Healthcare NHS Trust · 1 shared drug class
- Laboratoires Besins International · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Acerus Pharmaceuticals Corporation:
- Acerus Pharmaceuticals Corporation pipeline updates — RSS
- Acerus Pharmaceuticals Corporation pipeline updates — Atom
- Acerus Pharmaceuticals Corporation pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Acerus Pharmaceuticals Corporation — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/acerus-pharmaceuticals-corporation. Accessed 2026-05-17.